Todos Medical Ltd.
About Todos Medical Ltd.
Todos Medical is focused on developing an innovative, low cost, reliable and accessible early-cancer detection blood test. The Total Biochemical Infrared Analysis (TBIA) method makes up the foundation of the Company's core technology for the early detection of cancer by blood test. Todos Medical's initial focus is on the detection of breast and colon cancers using IVD tests which the Company believes will offer major advances over the current standards of care. The Company's pipeline includes plans to develop additional tests for other types of cancer.YEAR FOUNDED:
2010
LEADERSHIP:
Founder and CEO: Todos Medical
PRODUCTS:
All Products
FOLLOW TODOS MEDICAL:
Tweets by Todos Medical
129 articles with Todos Medical Ltd.
-
There’s quite a bit of movement on the Omicron-specific booster shot and updated supply deals, despite world leaders shifting their attention away from the COVID-19 pandemic.
-
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
6/30/2022
Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced biomarker data from its majority-owned joint venture 3CL Pharma Ltd.’s Phase 2 clinical trial of Tollovir™.
-
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
6/23/2022
Todos Medical, Ltd. (OTCQB: TOMDF) , a comprehensive medical diagnostics and related solutions company, today announced preliminary data from its majority-owned joint venture 3CL Pharma Ltd.’s ongoing IRB-waived sponsored market research study of the commercial use of Tollovid® as a dietary supplement.
-
Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics
6/13/2022
Todos Medical, Ltd. (OTCQB: TOMDF) , a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has completed validation of a 27-pathogen urinary tract infection (UTI) PCR precision medicine panel.
-
Todos Medical Reports Day 45 Update for Case Study #6
6/10/2022
Todos Medical, Ltd. announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 45 update from an ongoing case study by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary supplement, in a patient who originally contracted COVID in February 2021 and experienced symptoms of Long COVID.
-
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
6/7/2022
Todos Medical, Ltd. (OTCQB: TOMDF), today announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 28 update from an ongoing case study by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary supplement, in a patient who originally contracted COVID in December 2021 and experienced symptoms of Long COVID, including erectile dysfunction.
-
Todos Medical to Present at The LD Micro Conference
6/6/2022
Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced that Todos Medical President and CEO Gerald Commissiong will present at the LD Micro Conference on June 8, 2022.
-
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
6/3/2022
Todos Medical, Ltd. (OTCQB: TOMDF) , a comprehensive medical diagnostics and related solutions company, today announced that its academic partner, Dr. Thomas Arendt at Leipzig University, has completed full enrollment for 2nd cohort (confirmatory) for the ongoing clinical trial to evaluate the concordance of the LymPro Alzheimer’s Blood Test scores with amyloid PET imaging scores.
-
Todos Medical Reports Day 26 Update For Case Study #4
6/1/2022
Todos Medical, Ltd. announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 26 update from an ongoing 60-day case study by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary supplement, in a patient who originally contracted COVID in March 2021 and experienced symptoms of Long COVID.
-
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
5/27/2022
Todos Medical, Ltd. (OTCQB: TOMDF) , a comprehensive medical diagnostics and related solutions company, today announced that majority-owned subsidiary 3CL Pharma will present final data from the phase 2 clinical trial of Tollovir™ in the treatment of hospitalized (severe and critical) COVID-19 patients at the Personalized Medicine World Conference (PMWC) on June 30th, 2022 at 1:30pm Pacific Time.
-
Concerns are mounting for people that have been given Pfizer’s Paxlovid treatment regimen after contracting COVID-19, only to become positive for the infection once again.
-
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
5/6/2022
Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 14 update.
-
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
5/2/2022
Todos Medical, Ltd. (OTCQB: TOMDF), today announced that its majority-owned subsidiary 3CL Pharma, Ltd. has received a new certificate of free sale (CFS) from the US Food & Drug Administration whose label provides for both a 5-day support dosing regimen and a 30-day maintenance dosing regimen of Tollovid® Maximum Strength and reiterates the 3CL protease (3CLpro, Mpro, NSP5) in vitro inhibitor language allowed on prior labels for Tollovid®.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
4/21/2022
Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the appointment of Philippe Goix as Chief Commercial Officer for Todos Medical's wholly-owned CLIA/CAP certified lab, Provista Diagnostics.
-
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
4/20/2022
Todos Medical, Ltd. is reporting a case study from Dr. Lee Morgentaler of a patient who used Tollovid®, the Company’s 3CL protease inhibitor dietary supplement immune support product, after experiencing Long COVID symptoms.
-
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
4/4/2022
Todos Medical, Ltd. (OTCQB: TOMDF), today announced that its majority-owned subsidiary 3CL Pharma, Ltd. announced that its mechanism-based 3CL protease inhibitors Tollovir® and Tollovid™ that target the active site of the 3CL protease showed robust inhibitory activity against the 3CL protease of the BA.1 and BA.2 strains of the Omicron SARS-CoV-2 variant of concern (VOC).
-
Update: Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
4/1/2022
Todos Medical, Ltd. reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided corporate updates.
-
Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
4/1/2022
Todos Medical, Ltd. today reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided corporate updates.
-
Todos Medical to Present at the Proactive One2One Virtual Forum
3/17/2022
via NewMediaWire – Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced that Todos Medical President CEO Gerald Commissiong will present at the Proactive One2One Virtual Forum on March 17, 2022 at 2:00 PM ET.